| 0.3744 0.007 (1.99%) | 08-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Endo International plc operates as a specialty pharmaceutical firm, developing and marketing both proprietary brand-name and unbranded generic medications across the United States and global markets. Its Branded Pharmaceuticals division offers a diverse array of prescription products, notably including XIAFLEX for the treatment of Dupuytren's contracture in adults, SUPPRELIN LA to address central precocious puberty in children, NASCOBAL nasal spray for managing vitamin B12 deficiency, and AVEED for hypogonadism. Other significant branded offerings encompass QWO, an injectable solution for moderate to severe cellulite in adult women's buttocks; PERCOCET for moderate to moderately-severe pain; TESTOPEL, an implantable pellet indicated for testosterone replacement therapy (TRT); EDEX for erectile dysfunction; and LIDODERM, a topical patch designed to alleviate pain. This segment also includes other products aimed at pain management and urological conditions. The company's Sterile Injectables segment manufactures key products such as VASOSTRICT (a vasopressin injection), ADRENALIN (a non-selective adrenergic agonist), and APLISOL (a sterile aqueous solution), alongside various generic sterile injectable formulations like ertapenem and ephedrine sulfate. The Generic Pharmaceuticals segment provides a broad spectrum of formulations, including solid oral medications (both extended and immediate-release), liquids, semi-solids, transdermal patches, powders, ophthalmic solutions, and sprays. Internationally, the company's segment delivers specialized pharmaceutical products across multiple therapeutic areas, including attention deficit hyperactivity disorder, pain relief, women's health, oncology, and transplantation. Endo distributes its branded and generic offerings to a wide network of healthcare professionals and outlets, including specialty physicians, retailers, clinics, governmental bodies, individual doctors, retail and specialty pharmacies, and specialized distributors. Established in 1920, Endo International plc maintains its headquarters in Dublin, Ireland. A significant corporate development occurred on August 16, 2022, when Endo International plc and its affiliated entities voluntarily filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the Southern District of New York.
Wed, 19 Oct 2022
Endo International Plc - ENDP - Stock Price & News - The Motley Fool
Tue, 16 Aug 2022
Endo Creditors Eye Plan for Drugmaker’s Sale Through Bankruptcy (ENDP) - Bloomberg.com
Mon, 07 Feb 2022
Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles - PR Newswire
Wed, 22 Sep 2021
Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States - PR Newswire
Tue, 05 Jan 2021
Endo Aesthetics Launches “ Really Cellulite ” Campaign - MultiVu
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|